logo

Last Update

This profile was last updated on 8/2/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Didier Reymond?

Didier Reymond

Executive Vice President, Clinical Development

Thallion Pharmaceuticals Inc.

HQ Phone:  (514) 940-3600

Direct Phone: (514) ***-****direct phone

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Thallion Pharmaceuticals Inc.

1375 TransCanada Highway Suite 200

Dorval, Quebec,H9P 2W8

Canada

Company Description

Thallion Pharmaceuticals Inc. (TSX-V: TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. The Company's clinical programs include Shigamabs® and TLN-4601, a novel anti-cancer therapy. Shigamabs® i...more

Background Information

Employment History

Country Medical Director

Teva Canada Limited


Affiliations

Novartis AG

Medical Advisor


Education

Lausanne University , Medical School


Lausanne University Medical School


MD


Web References(7 Total References)


TEVA Canada Innovation - Our Executive Team

tevacanadainnovation.com [cached]

Didier Reymond
Didier Reymond Didier Reymond Didier Reymond Didier brings more than 20 years of pharmaceutical industry experience to his role of Country Medical Director at Teva Canada Innovation. Originally from Switzerland, Didier moved to Canada in 1994 to pursue a clinical fellowship in pediatric infectious diseases at The Hospital for Sick Children, Toronto. There, he conducted bench research activities on Verotoxin-producing Escherichia coli before completing his fellowship at Montreal's Sainte-Justine Pediatric University Hospital. Prior to joining Teva Canada Innovation, Didier held a variety of roles in the pharmaceutical industry, beginning in 1997 as manager, then Associate Director, Scientific, Affairs at Merck Frosst Canada, Merck Vaccine Division, before joining the Oncology Business Unit at the Novartis Pharmaceuticals Canada in 2002 as Medical Advisor, then Senior Medical Advisor for solid tumors. He also brings experience in biotechnology, as he was appointed VP Medical and Clinical Affairs in 2007, then Executive VP, Clinical Development at Thallion Pharmaceuticals in Montreal. Recruited by Pharmascience Canada Inc. in 2013, as Senior Director, Medical Affairs, he led a group of 60 professionals involved in Medical Information, Pharmacovigilance, Clinical Operations, Medical Affairs (MSLs, Medical Advisors) and Biopharmaceutics, before moving to Teva Canada Innovation in late 2016. Didier graduated from Lausanne University Medical School, Switzerland in December 1987. He began his residency in pediatrics at the Lausanne University Hospital Centre before completing his training at the Pediatric University Hospital of Bern, Switzerland, and being board certified in 1994.


www.tevacanadainnovation.ca

Didier Reymond
Didier Reymond Didier Reymond Didier Reymond Didier brings more than 20 years of pharmaceutical industry experience to his role of Country Medical Director at Teva Canada Innovation. Originally from Switzerland, Didier moved to Canada in 1994 to pursue a clinical fellowship in pediatric infectious diseases at The Hospital for Sick Children, Toronto. There, he conducted bench research activities on Verotoxin-producing Escherichia coli before completing his fellowship at Montreal's Sainte-Justine Pediatric University Hospital. Prior to joining Teva Canada Innovation, Didier held a variety of roles in the pharmaceutical industry, beginning in 1997 as manager, then Associate Director, Scientific, Affairs at Merck Frosst Canada, Merck Vaccine Division, before joining the Oncology Business Unit at the Novartis Pharmaceuticals Canada in 2002 as Medical Advisor, then Senior Medical Advisor for solid tumors. He also brings experience in biotechnology, as he was appointed VP Medical and Clinical Affairs in 2007, then Executive VP, Clinical Development at Thallion Pharmaceuticals in Montreal. Recruited by Pharmascience Canada Inc. in 2013, as Senior Director, Medical Affairs, he led a group of 60 professionals involved in Medical Information, Pharmacovigilance, Clinical Operations, Medical Affairs (MSLs, Medical Advisors) and Biopharmaceutics, before moving to Teva Canada Innovation in late 2016. Didier graduated from Lausanne University Medical School, Switzerland in December 1987. He began his residency in pediatrics at the Lausanne University Hospital Centre before completing his training at the Pediatric University Hospital of Bern, Switzerland, and being board certified in 1994.


www.canadianlifesciences.com

Dr. Didier Reymond
Executive Vice-President, Clinical Development dreymond@thallion.com


Management : Thallion Pharmaceuticals

www.ecopiabio.com [cached]

Didier Reymond, MD
Executive Vice-President, Clinical Development Dr. Reymond leads clinical development for all phases ofThallion's clinicalprograms. Before Thallion, he was a Senior Medical Advisorwith Novartis Canada, leading the medical and clinical activities for solid tumors. Prior to that, Dr. Reymond was Associate Director, Scientific Affairs, for the Merck Vaccine Division, Merck Frosst Canada. He was responsible for Regulatory Affairs and Medical Affairs for all vaccines in Canada. Dr. Reymond graduated from Lausanne University, Medical School,before working in Pediatric Surgery and completing his residency in Pediatrics at the University Hospitals of Lausanne and Bern.Board certified in Pediatrics, Dr. Reymond pursued a Fellowship in Pediatric Infectious Diseases at The Hospital for Sick Children, Toronto, where he conducted research activities on Verotoxin-producing Escherichia coli. Dr. Reymond completed his fellowship program at the Hôpital Sainte-Justine, in Montreal, conducting pediatric clinical research focusing on oral antibiotics.


www.arena-international.com

Didier Reymond
VP Clinical Development Thallion Pharmaceuticals


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory